Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 11-17 of 17 (Search time: 0.003 seconds).
previous
1
2
next
Item hits:
Preview
Issue Date
Title
Author(s)
2009
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Branford, S.
;
Vaz de Melo, J.
;
Hughes, T.
2012
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
Branford, S.
;
Yeung, D.
;
Prime, J.
;
Choi, S.
;
Bang, J.
;
Park, J.
;
Kim, D.
;
Ross, D.
;
Hughes, T.
2011
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells
Tang, M.
;
Gonen, M.
;
Quintas-Cardama, A.
;
Cortes, J.
;
Kantarjian, H.
;
Field, C.
;
Hughes, T.
;
Branford, S.
;
Michor, F.
2003
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
Branford, S.
;
Rudzki, Z.
;
Walsh, S.
;
Parkinson, I.
;
Grigg, A.
;
Szer, J.
;
Taylor, K.
;
Hermann, R.
;
Seymour, J.
;
Arthur, C.
;
Joske, D.
;
Lynch, K.
;
Hughes, T.
2010
Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
Cortes, A.
;
Baccarani, M.
;
Guilhot, F.
;
Druker, B.
;
Branford, S.
;
Kim, D.
;
Pane, F.
;
Pasquini, R.
;
Goldberg, S.
;
Kalaycio, M.
;
Moiraghi, B.
;
Rowe, J.
;
Tothova, E.
;
de Souza, C.
;
Rudoltz, M.
;
Yu, R.
;
Krahnke, T.
;
Kantarjian, H.
;
Radich, J.
;
Hughes, T.
2011
BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib teatment
Stein, A.
;
Bottino, D.
;
Modur, V.
;
Branford, S.
;
Kaeda, J.
;
Goldman, J.
;
Hughes, T.
;
Radich, J.
;
Hochhaus, A.
2011
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia
Esposito, N.
;
Colavita, I.
;
Quintarelli, C.
;
Sica, A.
;
Peluso, A.
;
Luciano, L.
;
Picardi, M.
;
Vecchio, L.
;
Buonomo, T.
;
Hughes, T.
;
White, D.
;
Radich, J.
;
Russo, D.
;
Branford, S.
;
Saglio, G.
;
Vaz de Melo, J.
;
Martinelli, R.
;
Ruoppolo, M.
;
Kalebic, T.
;
Martinelli, G.
;
et al.
Discover
Author
6
Radich, J.
4
Grigg, A.
4
Hochhaus, A.
4
Rudzki, Z.
4
Seymour, J.
3
Arthur, C.
3
Goldman, J.
3
Kaeda, J.
3
Ross, D.
3
Vaz de Melo, J.
.
next >
Subject
17
Benzamides
17
Humans
17
Piperazines
17
Pyrimidines
16
Leukemia, Myelogenous, Chronic, B...
12
Fusion Proteins, bcr-abl
11
Antineoplastic Agents
9
Adult
9
Female
9
Male
.
next >
Date issued
9
2010 - 2013
8
2002 - 2009